RHHBY
OTC · Healthcare
Roche Holding AG
$47.39
-1.03 (-2.12%)
RHHBY News30 articles
BP Shares Slide as Crude Plunge Erases Refinery Sale Gains
BP shares declined 4.2% in London trading after Brent crude prices fell 10.9% to $99.94 per barrel. The drop offset recent gains driven by the company's refinery sale and cost-cutting initiatives.
Indian Markets Rebound Sharply on Easing Oil Prices and IT Rally
Indian equity indices staged a strong recovery on March 20, 2026, with the Sensex jumping 891 points. The rally was fueled by falling crude oil prices and a surge in IT stocks.
Markets Mixed as Bitcoin Soars, Texas Emerges as Financial Hub
Global markets showed divergent trends with Bitcoin climbing above $75,000 as a digital safe haven, while Indian equities recovered strongly. Texas solidified its position as a major financial center with new exchange launches.
Iran Conflict Fuels Global Inflation Surge as Oil Tops $100
The Iran conflict has triggered a severe oil supply disruption, pushing Brent crude above $100 a barrel and sending shockwaves through global freight, agriculture, and consumer markets.
India Races to Secure LPG Amid Gulf War Disruption, Sparks Induction Stove Rush
India has invoked emergency powers to redirect LPG supplies from commercial to residential users following Gulf war disruptions, causing restaurants to limit hot meals and triggering a massive spike in induction cooker purchases.
FTSE 100 Retreats on Oil Spike, Rate Cut Hopes Dim
London's FTSE 100 declined 0.7% in early Thursday trading as Brent crude surged past $100 a barrel, dampening expectations for near-term Bank of England rate cuts and pressuring consumer-focused sectors.
BAE Systems Shares Dip Amid European Defense Sector Sell-Off
BAE Systems' stock declined alongside a broader drop in European defense shares after Rheinmetall's sales forecast disappointed. The company reported a record order backlog and continues its share repurchase program.
AbbVie's Early Obesity Drug Trial Shows Promising Weight Loss Results
AbbVie reported its amylin-based obesity candidate ABBV-295 led to significant weight reduction in an early study, with no serious safety issues observed. The data marks a strategic step for the company as it seeks growth beyond immunology.
Middle East Conflict Sparks Historic Oil Price Surge, Strains Global Supply
Oil prices surged dramatically on Monday, with Brent crude briefly exceeding $119 per barrel, following supply disruptions in the Middle East linked to regional conflict. Governments and companies scrambled to respond to the market shock.
FTSE 100 Plunges on Oil Price Surge and Geopolitical Tensions
London's FTSE 100 index opened sharply lower, dropping 1.75%, as a surge in crude oil prices above $119 per barrel rattled markets. The spike, driven by Middle East supply concerns, particularly punished airline and mining shares.
Global Markets Plunge as Oil Surge Sparks Inflation Fears
Global equity markets faced a severe selloff on March 9, 2026, driven by a sharp spike in oil prices above $115 per barrel and escalating Middle East tensions. Japan's Nikkei 225 plunged 7%, while India's Sensex crashed over 2,400 points.
Microsoft's $409 Level in Focus as AI Demand Meets Inflation Test
Microsoft shares closed at $408.96, down slightly amid a broader tech sell-off. Investors are balancing positive AI demand indicators from partners like Broadcom against looming inflation data and macroeconomic concerns.
Zealand Pharma Stock Crashes on Obesity Drug Data Lagging Lilly
Zealand Pharma A/S shares plunged over 32% Friday after mid-stage trial results for its obesity drug candidate petrelintide showed weight loss well behind Eli Lilly's competing therapy, erasing billions in market value.
U.S. Drafts New AI Chip Export Rules, Potentially Impacting AMD, Nvidia
U.S. officials are drafting new AI chip export regulations that could require foreign governments to invest in U.S. data centers or provide security guarantees, potentially impacting major chipmakers like AMD, Nvidia, and Intel.
EU's 'Made in EU' Rules Threaten Ford's Supply Chain
The European Commission has proposed strict 'Made in EU' rules linking subsidies to local content, potentially excluding Ford's key suppliers in Britain and Turkey. The plan faces significant opposition and requires approval.
Iran's Strait of Hormuz Control Threatens Global Oil Flows, Prices Surge
Iran's declaration of control over the Strait of Hormuz has triggered a sharp slowdown in tanker traffic and a 4.7% spike in Brent crude prices. Analysts warn Asian economies are most vulnerable to supply disruptions.
Gold, Oil Spike as Middle East Strikes Rattle Markets
Gold and oil prices surged Monday as U.S. and Israeli strikes on Iran escalated regional tensions, sending investors toward safe havens while equities declined.
Merck's Keytruda, Welireg Data and FDA Dates Drive Stock Momentum
Merck stock gained after reporting Phase 3 survival data for Keytruda in ovarian and kidney cancers. The FDA set 2026 review dates for Welireg combinations.
Swiss Market Index Breaks 14,000 as Earnings and Regulation Drive Focus
The Swiss Market Index surpassed the 14,000-point threshold to close February at a record high. Investor attention shifts to corporate earnings from Swiss Re and Holcim, alongside regulatory pressures on UBS.
Microsoft Shares Rebound Amid AI Investment and Regulatory Scrutiny
Microsoft shares gained about 1% to $404.50 in early Thursday trading, recovering from a significant year-to-date decline. The move follows a major AI investment, regulatory action in Japan, and upcoming White House discussions on data center energy costs.
Silver Surges Past $80 on Safe-Haven Demand Ahead of Key U.S. Data
Silver prices climbed nearly 3% to breach $80 per ounce in European trading Friday, driven by safe-haven demand amid Middle East tensions and lower bond yields. The rally is increasing costs for solar manufacturers.
RELX Shares Dip on Buyback Activity and Insider Transactions
Shares of RELX PLC declined in early London trading as the market processed regulatory filings showing ongoing share repurchases and an executive transaction. The information services giant continues its capital return program against a backdrop of shifting UK monetary policy expectations.
Robinhood's February Metrics in Focus Amid Bitcoin Volatility
Robinhood Markets will report its January monthly metrics on February 19, following a holiday-shortened week. The update comes as Bitcoin pulls back from recent peaks, potentially impacting the platform's crypto-related revenue.
GE Aerospace Boosts Engine Repair with Robotics Amid Airbus Pressure
GE Aerospace shares gained 0.8% to $315.41 as the company implements robotic automation to accelerate jet-engine repairs. Airbus continues pressing CFM for increased LEAP engine deliveries.
St. James's Place Recovers After AI-Driven Selloff, Focus Turns to Earnings
St. James's Place shares rose 2.6% in London trading, partially recovering from a 13.4% plunge triggered by AI tax tools from U.S. startup Altruist. Investors now await the wealth manager's full-year results on February 25.
Pfizer Shares Dip in Premarket Amid SEC Settlement, Partnership News
Pfizer stock edged lower in premarket trading following a $29 million SEC settlement agreement and a new biotech incubator partnership. Investors await key inflation data.
Reckitt Shares Dip Amid Dividend Focus and Margin Uncertainty
Reckitt shares declined 0.6% in early London trading as investors await a special dividend and full-year results. Broker caution persists over U.S. litigation and 2026 margin outlook.
Novartis Shares Approach 52-Week Peak Amid San Diego Research Expansion
Novartis stock neared a 52-week high after breaking ground on a major San Diego research center, while investors eye upcoming shareholder events and 2026 profit guidance.
Roche's MS Drug Trial Results Set Stage for Monday Investor Scrutiny
Roche's fenebrutinib met its primary endpoint in a late-stage PPMS trial, showing non-inferiority to Ocrevus but with higher liver enzyme elevations and fatal cases. Shares closed at 356.40 Swiss francs, down 0.6%.
Roche's MS Drug Trial Results Spark Investor Scrutiny Ahead of Key Presentation
Roche's experimental multiple sclerosis drug fenebrutinib met its primary endpoint in a late-stage study but showed higher liver enzyme elevations and fatalities versus Ocrevus. Investors await Monday's detailed data webcast.